| Market Cap | 237.81M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -89.94M | Forward P/E | -5.30 | EPS next Y | - | 50D Avg Chg | -14.00% |
| Sales | 3.03M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 3.47 | EPS next 5Y | 46.30% | 52W High Chg | -34.00% |
| Recommedations | 2.40 | Quick Ratio | 6.70 | Shares Outstanding | 63.25M | 52W Low Chg | 36.00% |
| Insider Own | 0.58% | ROA | -37.05% | Shares Float | 33.80M | Beta | 1.26 |
| Inst Own | 76.11% | ROE | -133.81% | Shares Shorted/Prior | 756.01K/2.61M | Price | 3.76 |
| Gross Margin | 95.78% | Profit Margin | - | Avg. Volume | 996,380 | Target Price | - |
| Oper. Margin | -2,408.65% | Earnings Date | Mar 2 | Volume | 8,196,718 | Change | -6.00% |
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
| Jefferies | Buy | Aug 13, 20 |
| HC Wainwright & Co. | Buy | Aug 12, 20 |
| HC Wainwright & Co. | Buy | Jun 29, 20 |
| HC Wainwright & Co. | Buy | Mar 17, 20 |
| Piper Jaffray | Overweight | Jul 31, 19 |
| Cantor Fitzgerald | Overweight | Mar 7, 19 |
| H.C. Wainwright | Buy | Feb 14, 19 |
| Barclays | Underweight | Jan 17, 17 |
| Barclays | Equal-Weight | Apr 24, 16 |